President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I ...

President Joe Biden wants Medicare and Medicaid to cover weight loss drugs, a proposal that would expand access to the costly but life-changing medications for millions of people who struggle with ...

Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...

The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

New weight-loss medications are reshaping U.S. healthcare by increasing diagnoses of obesity-related conditions and encouraging patients' engagement with health services. These drugs, including Wegovy ...